GEN Exclusives

More »

GEN News Highlights

More »
Sep 16, 2009

PerkinElmer Buys GE’s Catalog Radiochemicals, SPA Reagents, and Cytostar-T Plate Assets

  • PerkinElmer has purchased the assets of GE Healthcare’s 3H and 14C Catalog Radiochemicals, Scintillation Proximity Assay (SPA) reagents, and Cytostar-T plate product lines.

    The Catalog Radiochemical products are used for a variety of research applications including screening of potential drug candidates through binding assays. The SPA bead-based, light-emitting assay and Cytostar-T plate technologies enable the automation of high-throughput screening (HTS) processes.

    “We expect that the incorporation of these technologies will strengthen our industry-leading GPCR and kinase research product lines and complement our HTS and research reagent solutions,” says Richard M. Eglen, Ph.D., president, Bio-discovery, PerkinElmer.

    PerkinElmer plans to continue expanding its NEN® radiochemical portfolio. The company’s solutions in radiometric detection include lines of readers, nuclear counters, and other instrumentation.


Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »